Nachrichten zur Intellia Therapeutics Inc. Aktie

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics Announces CFO Transition

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics: "buy"

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist stufen die Aktie von Intellia Therapeutics Inc. (ISIN: US45826J1051, WKN: A2AG6H, Ticker-Symbol:…

Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Nachrichten zur Intellia Therapeutics Inc. Aktie

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Intellia Therapeutics Announces CFO Transition

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Intellia Therapeutics: "buy"

Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

Is Intellia Therapeutics Stock a Buy Now?

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

dpa-AFX ProFeed